Detail akcie Silexion Rg online

Business Summary: Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Silexion Therapeutics Corp revenues was not reported. Net loss decreased 49% to $7.5M. Lower net loss reflects Share-based compensation expenses decrease of 97% to $96K (expense), Share-based compensation expenses decrease from $2.4M (expense) to $0K, Foreign currency exchange loss, net decrease of 56% to $87K (expense).